within Pharmacolibrary.Drugs.ATC.S;

model S01AA26
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 630 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 0.031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Azithromycin is a macrolide antibiotic used for the treatment of various bacterial infections, including respiratory tract, skin, ear, and eye infections. For ophthalmic use (ATC code S01AA26), it is primarily used as eye drops for bacterial conjunctivitis. Azithromycin is approved for medical use and routinely prescribed in clinical practice.</p><h4>Pharmacokinetics</h4><p>Ophthalmic administration, healthy adults, pharmacokinetic parameters estimated from available publications focused mainly on systemic use; direct ophthalmic PK parameters are limited.</p><h4>References</h4><ol><li><p>Sakai, T, et al., &amp; Kawamura, A (2019). Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. <i>Ophthalmology and therapy</i> 8(4) 511–517. DOI:<a href=&quot;https://doi.org/10.1007/s40123-019-00205-0&quot;>10.1007/s40123-019-00205-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31372937/&quot;>https://pubmed.ncbi.nlm.nih.gov/31372937</a></p></li><li><p>Garnock-Jones, KP (2012). Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis. <i>Drugs</i> 72(3) 361–373. DOI:<a href=&quot;https://doi.org/10.2165/11208580-000000000-00000&quot;>10.2165/11208580-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22316352/&quot;>https://pubmed.ncbi.nlm.nih.gov/22316352</a></p></li><li><p>Akpek, EK, et al., &amp; Crean, C (2009). Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 25(5) 433–439. DOI:<a href=&quot;https://doi.org/10.1089/jop.2009.0026&quot;>10.1089/jop.2009.0026</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19857105/&quot;>https://pubmed.ncbi.nlm.nih.gov/19857105</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01AA26;
